ObsEva: Gains on additional positive data for menstrual drug from late-stage trials

Obseva SA

10/12/2020 12:22

** U.S.-listed shares of Swiss drug developer  OBSV.O  rise
11% to $2.32 premarket - set for a near two-mth high
    ** OBSV reports additional positive results from two
late-stage trials of Yselty, its experimental treatment for
women with heavy menstrual bleeding due to uterine fibroids
 urn:newsml:reuters.com:*:nGNEbyCWHj
    ** Pooled results from the two studies showed that at week
52, 56.4% of women treated with a 100 mg dose of Yselty met the
main goal of reduced heavy menstrual bleeding
    ** Co expects to submit a marketing application to the U.S.
FDA in H1 2021
    ** Up to Wednesday's close, stock down 45.3% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))